FAP: The Next Billion Dollar Nuclear Theranostics Target?
Jérémie Calais
Abstract
The recent successful clinical translation of nuclear theranostics ([1][1],[2][2]) fueled industry investment in the radiopharmaceutical market ([3][3]). Among other examples, Novartis invested $6 billion to acquire Endocyte (177Lu-PSMA-617) and Advanced Accelerator Applications (AAA; 177Lu-DOTATATE
Topics & Concepts
Liberian dollarInvestment (military)BusinessMedical physicsMedicineNuclear medicineFinancePolitical scienceLawPoliticsPeptidase Inhibition and AnalysisRadiopharmaceutical Chemistry and ApplicationsNeuroendocrine Tumor Research Advances